CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

Exclusion Criteria

• •To be eligible for this protocol, subjects must not:
• •1. Have any active infectious illness.
• •2. Have had a prior HAE attack and/or received any C1 INH product within 7 days prior to dosing with study drug.
• •3. Have received therapy with antifibrinolytics (e.g., tranexamic acid), androgens (e.g., danazol, oxandrolone, stanozolol, or testosterone), ecallantide (Kalbitor®), or icatibant (Firazyr®) within 7 days prior to dosing with study drug.
• •4. Have a history of allergic reaction to C1 INH products, including CINRYZE (or any of the components of CINRYZE), or other blood products.
• •5. Have participated in any other investigational drug evaluation within 30 days prior to dosing with study drug, or have previously received treatment with CINRYZE in this study at any time.